NASDAQ:SGMT Sagimet Biosciences (SGMT) Stock Price, News & Analysis $10.42 -0.67 (-6.04%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$10.14 -0.28 (-2.68%) As of 06:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sagimet Biosciences Stock (NASDAQ:SGMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sagimet Biosciences alerts:Sign Up Key Stats Today's Range$10.15▼$11.2650-Day Range$7.01▼$11.1752-Week Range$4.50▼$11.45Volume1.12 million shsAverage Volume911,334 shsMarket Capitalization$647.70 millionP/E RatioN/ADividend YieldN/APrice Target$27.96Consensus RatingModerate Buy Company Overview Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies for diseases associated with abnormal lipid metabolism. The company’s primary focus is fatty acid synthase (FASN), an enzyme involved in the production of fatty acids that can contribute to disease progression in certain metabolic and inflammatory conditions. Sagimet’s lead product candidate is denifanstat, formerly known as TVB-2640. Denifanstat is an orally administered, selective FASN inhibitor being evaluated primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can lead to fibrosis, cirrhosis and other serious complications. The company has also investigated FASN inhibition in additional disease areas, including oncology and dermatological conditions. Originally established as 3-V Biosciences, Sagimet Biosciences is headquartered in San Mateo, California, and conducts clinical development activities intended to support potential regulatory approval of its therapies. Its research and development programs are focused on translating FASN biology into medicines for patients with significant unmet medical needs.AI Generated. May Contain Errors. Read More Sagimet Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreSGMT MarketRank™: Sagimet Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 291st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSagimet Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSagimet Biosciences has a consensus price target of $27.96, representing about 168.3% upside from its current price of $10.42.Amount of Analyst CoverageSagimet Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sagimet Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sagimet Biosciences are expected to grow in the coming year, from ($1.19) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sagimet Biosciences is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sagimet Biosciences is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSagimet Biosciences has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sagimet Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.38% of the float of Sagimet Biosciences has been sold short.Short Interest Ratio / Days to CoverSagimet Biosciences has a short interest ratio ("days to cover") of 9.58.Change versus previous monthShort interest in Sagimet Biosciences has recently decreased by 13.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSagimet Biosciences does not currently pay a dividend.Dividend GrowthSagimet Biosciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest6 people have searched for SGMT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sagimet Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $920,491.00 in company stock.Percentage Held by Insiders11.50% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sagimet Biosciences' insider trading history. Receive SGMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGMT Stock News HeadlinesCantor Fitzgerald initiates coverage of Sagimet Biosciences at overweightSeptember 9, 2026 | msn.comBarclays upgrades Sagimet Biosciences to overweight from equal-weightSeptember 9, 2026 | msn.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 24 at 1:00 AM | Paradigm Press (Ad)Sagimet Biosciences Announces Participation in Two Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comSagimet Biosciences Announces AURORA Phase 3 Acne Trial on Track to Begin Enrollment in Q4 2026August 25, 2026 | quiverquant.comQSagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026August 25, 2026 | globenewswire.comSagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 17, 2026 | markets.businessinsider.comSagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 17, 2026 | globenewswire.comSee More Headlines SGMT Stock Analysis - Frequently Asked Questions How have SGMT shares performed this year? Sagimet Biosciences' stock was trading at $5.92 at the start of the year. Since then, SGMT shares have increased by 76.0% and is now trading at $10.42. How were Sagimet Biosciences' earnings last quarter? Sagimet Biosciences Inc. (NASDAQ:SGMT) announced its earnings results on Tuesday, August, 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. When did Sagimet Biosciences IPO? Sagimet Biosciences (SGMT) raised $85 million in an IPO on Friday, July 14th 2023. The company issued 5,312,500 shares at a price of $15.00-$17.00 per share. Who are Sagimet Biosciences' major shareholders? Top institutional investors of Sagimet Biosciences include Seven Fleet Capital Management LP (1.24%), Bank of New York Mellon Corp (0.62%), FNY Investment Advisers LLC (0.34%) and AWM Investment Company Inc. (0.25%). Insiders that own company stock include David Happel, Elizabeth Rozek, Eduardo Bruno Martins, George Kemble and Thierry Chauche. View institutional ownership trends. How do I buy shares of Sagimet Biosciences? Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sagimet Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sagimet Biosciences investors own include XPENG (XPEV), Iovance Biotherapeutics (IOVA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Tenet Healthcare (THC) and Urogen Pharma (URGN). Company Calendar Last Earnings8/11/2026Today9/24/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SGMT's financial health is in the Green zone, according to TradeSmith. SGMT has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMT CIK1400118 Websagimet.com Phone650-561-8600FaxN/AEmployees16Year Founded2006Price Target and Rating Average Price Target for Sagimet Biosciences$27.96 High Price Target$56.00 Low Price Target$10.71 Potential Upside/Downside+168.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.96% Return on Assets-30.57% Debt Debt-to-Equity RatioN/A Current Ratio45.03 Quick Ratio45.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book3.05Miscellaneous Outstanding Shares62,159,000Free Float55,011,000Market Cap$647.70 million OptionableOptionable Beta3.45 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:SGMT) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredThe REAL Reason 2,000 Missiles Rained on IranTwo private meetings with U.S. Congressmen and weeks of research point to a surprising explanation for the rec...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
